Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson reports healthcare developments across its Innovative Medicine and MedTech businesses. News commonly covers clinical and scientific data in immunology, oncology, neurology and neuropsychiatry, including medicines and candidates such as CAPLYTA, TREMFYA, JNJ-4804, seltorexant and the INVEGA long-acting injectable schizophrenia portfolio.
Company updates also include medical technology programs such as the investigational OTTAVA robotic surgical system, product and patient-education initiatives, quarterly sales and earnings releases, dividend actions, investor presentations and governance or investor-relations appointments.
Johnson & Johnson (NYSE: JNJ) announced that the U.S. FDA has granted Priority Review to a supplemental Biologics License Application for subcutaneous RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as a potential treatment for adults with recurrent or metastatic head and neck squamous cell carcinoma whose disease has progressed after platinum-based chemotherapy and PD‑1/PD‑L1 therapy.
The Priority Review, which shortens review to about six months, is supported by pivotal Phase 1b/2 OrigAMI‑4 data showing a 42% overall response rate with monotherapy subcutaneous amivantamab, with more than one‑third of responders achieving complete responses. RYBREVANT FASPRO is already approved in over 40 countries as a subcutaneous therapy for EGFR‑mutated non‑small cell lung cancer and is the only therapy in head and neck cancer engineered to target both EGFR and MET.
Johnson & Johnson (NYSE: JNJ) has completed its acquisition of Firefly Bio, a biotechnology company developing the proprietary Firelink™ degrader antibody conjugate (DAC) platform, for $1 billion in cash. The deal broadens Johnson & Johnson’s oncology portfolio and is intended to advance targeted therapies for difficult-to-treat solid tumors, including KRAS-driven cancers.
According to the company, the Firelink™ DAC platform is designed to deliver highly selective protein degraders directly to cancer cells, aiming to maximize tumor targeting while preserving healthy tissue. The transaction will be accounted for as an asset acquisition, creating an approximately $1 billion in-process R&D charge in Q3 2026 and is expected to dilute adjusted EPS by about $0.46 in 2026 and $0.08 in 2027.
Johnson & Johnson (NYSE: JNJ) announced strategic agreements with Sail Biomedicines to advance in vivo CAR-T programs for immune‑mediated diseases and expand Sail’s platform to additional targets. The collaboration agreement is with Janssen Biotech, a Johnson & Johnson company, and the equity investment is made by Johnson & Johnson Innovation – JJDC.
According to Johnson & Johnson, total initial payments are expected to be $785 million, including a $465 million equity investment and up to $140 million in contingent development milestone payments. Johnson & Johnson also receives an exclusive option to acquire Sail for $2.58 billion. If the option is exercised, the company expects dilution of approximately $0.18 to adjusted operational EPS and adjusted EPS in 2026 and approximately $1.28 in 2027. The transactions are subject to regulatory approvals and other conditions.
Covista (NYSE: CVSA) appointed Emily C. Chiu and Leslie Storms to its Board of Directors, effective August 17, 2026, as the company advances its three-year “Purpose at Scale” growth strategy to address U.S. healthcare workforce shortages.
Chiu brings CEO-level experience in technology, fintech and edtech, including leadership roles at Novo Platform and Block’s open-source platform and Cash App. Storms is Chief Operating Officer of National Veterinary Associates and previously held senior MedTech leadership roles at Johnson & Johnson. With these appointments, 10 of Covista’s 12 directors are independent, supporting governance as the company focuses on operational excellence, expansion into adjacent healthcare domains, direct workforce pipelines with employer partners and AI-enabled healthcare education innovation.
Johnson & Johnson (NYSE: JNJ) announced an agreement in principle to comprehensively resolve its remaining ovarian talc litigation with plaintiff firms leading the federal MDL and related state cases. The proposed resolution is conditioned on participation covering at least 95% of the remaining roughly 76,000 claims.
The structure calls for per-claim payments within a $5.5 billion total commitment, with a first payment of no more than $3 billion in 2027 and no further payments before 2028. According to the company, this follows a favorable MDL specific-causation ruling and complements prior settlements of about 95% of mesothelioma suits, all state consumer protection actions, and all talc-supplier disputes.
Johnson & Johnson (NYSE: JNJ) reported positive topline results from the Phase 3 MonumenTAL-6 trial in adults with relapsed or refractory multiple myeloma after 1–4 prior therapies, including an anti-CD38 antibody and lenalidomide. The study compared TECVAYLI + TALVEY (Tec-Tal) and TALVEY + pomalidomide (Tal-P) against investigator’s choice of EPd or PVd standard regimens.
According to Johnson & Johnson, Tec-Tal reduced the risk of disease progression or death by 89% (HR 0.11; 95% CI 0.08–0.16; p<0.0001) and the risk of death by 62% (HR 0.38) versus standard of care, with Tal-P reducing progression or death risk by 73% (HR 0.27; 95% CI 0.2–0.35). Both investigational arms met the primary endpoint of progression-free survival, and safety was described as consistent with the known profiles of each monotherapy. An Independent Data Monitoring Committee recommended unblinding at the first interim analysis, and full data will be presented at a future medical meeting and shared with regulators.
Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has granted De Novo market authorization for its OTTAVA™ Robotic Surgical System, described as the world’s first table-integrated soft tissue robotic system. According to Johnson & Johnson, OTTAVA is authorized for multiple general surgery procedures in the upper abdomen, including gastric bypass, gastrectomy, gastric sleeve, cholecystectomy, splenectomy, small bowel resection, appendectomy, lysis of adhesions, fundoplication and hiatal hernia repair.
The company plans a phased U.S. commercial launch with select customers while it pursues additional indications and regulatory jurisdictions. First-generation features include four table-integrated robotic arms with automated poses and synchronized table/arm motion, a reengineered instrumentation portfolio, and connectivity to the Polyphonic™ digital ecosystem to support data-driven surgery and education programs for robotic surgeons.
Johnson & Johnson (NYSE: JNJ) announced a collaboration with TIME to launch the branded Healthcare Champion of the Year award, honoring U.S. healthcare professionals whose care, innovation and grit are advancing patient care and health systems.
Nominations for the inaugural TIME Healthcare Champion of the Year, in partnership with Johnson & Johnson, open on July 16, 2026 and close at 5:00 p.m. ET on August 28, 2026 via the company’s website. Eligible nominees include a wide range of healthcare professionals actively involved in clinical care or care delivery in the U.S., at any career stage, who demonstrate real-world impact aligned to core themes of grit, innovation or patient care. The honoree will be announced ahead of TIME’s “A Year in TIME” celebration on December 9, 2026 in New York City. Johnson & Johnson links this initiative to its broader J&J CareCommunity platform and its long-standing commitment to supporting nurses, community health workers and the global health workforce.
DePuy Synthes (NYSE:JNJ) announced the acquisition of Expanding Innovations, a commercial-stage medical technology company specializing in expandable implant technologies for spine surgery. The deal is intended to strengthen DePuy Synthes’ Spine portfolio and expand its position in the rapidly growing expandable interbody cage market.
Expanding Innovations’ proprietary, non-screw-based interbody cage technology is designed to help reduce post-operative cage collapse and vertebral body subsidence while supporting procedural efficiency and implant stability. Its X-PAC portfolio includes TLIF and LLIF expandable cages and the N-GAGE Lumbar Plate System, with planned expansion into next-generation TLIF/LLIF cages, enhanced instrumentation, and future ALIF solutions. According to DePuy Synthes, Expanding Innovations’ technology will complement the TriALTIS Spine System and be integrated into the VELYS Enabling Tech portfolio for Spine.
Johnson & Johnson (NYSE: JNJ) declared a third-quarter 2026 cash dividend of $1.34 per share on its common stock.
The dividend is payable on September 8, 2026 to shareholders of record and with an ex-dividend date of August 25, 2026.